Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. - Wikidata - awgldk - TriplyDB

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

http://www.wikidata.org/entity/Q33968031

about

Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy Mammalian target of rapamycin inhibitors for heart transplant patients mTOR inhibitors in advanced renal cell carcinoma Next-generation drug-eluting stents in coronary artery disease: focus on everolimus-eluting stent (Xience V)Mammalian target of rapamycin inhibitors for heart transplant patients Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation Drug Eluting Stents for Malignant Airway Obstruction: A Critical Review of the Literature Everolimus-eluting stent platforms in percutaneous coronary intervention: comparative effectiveness and outcomes Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials Non-viral infections in children after renal transplantation Targeting the intragraft microenvironment and the development of chronic allograft rejection MHC class I signaling: new functional perspectives for an old molecule Cardiac allograft vasculopathy: diagnosis, therapy, and prognosis.Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Immune-mediated vascular injury and dysfunction in transplant arteriosclerosis Management of allosensitized cardiac transplant candidates Oral rapamycin attenuates inflammation and enhances stability of atherosclerotic plaques in rabbits independent of serum lipid levels.Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data.Sirolimus reduces vasculopathy but exacerbates proteinuria in association with inhibition of VEGF and VEGFR in a rat kidney model of chronic allograft dysfunction.Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy.Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.The pros and the cons of mTOR inhibitors in kidney transplantation.The role of CYP3A5 genotypes in dose requirements of tacrolimus and everolimus after heart transplantation.[Biomarker for diagnosis of rejection after heart transplantation].Phase I clinical and pharmacokinetic study of RAD001 (everolimus) administered daily to Japanese patients with advanced solid tumors Surgical biology for the clinician: vascular effects of immunosuppression Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.Immunoregulatory functions of mTOR inhibition.Everolimus in patients with severe pulmonary hypertension: a safety and efficacy pilot trial.Cardiac allograft vasculopathy: current knowledge and future direction.Multiple indications for everolimus after liver transplantation in current clinical practice.Coronary microvasculopathy in heart transplantation: Consequences and therapeutic implications.Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors.Immunosuppression for lung transplantation.The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.Pediatric heart transplantation-indications and outcomes in the current era.Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling.Steroid-free and steroid withdrawal protocols in heart transplantation: the review of literature.Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I Immunological advantages of everolimus versus cyclosporin A in liver-transplanted recipients, as revealed by polychromatic flow cytometry.

P2860

Q21198871-87B7ACC6-F68D-4480-90BB-A0364E611E57 Q24194002-CDD4A4C1-98A2-446D-84E9-1624B562B522 Q24612127-4E064222-B01F-4381-B969-506C3A765F08 Q24642679-A2FAFA40-B334-436B-9670-4806197261B8 Q26470671-89F2F708-0348-4478-A95E-2979FE0B3BEC Q26751433-D7E408FE-101E-4BFF-9AF1-99FDD5DE0062 Q26766244-98D37BE7-2D6D-4B17-AA8F-D88AAA099DE1 Q26798582-E1843B2E-2967-49DC-B50F-8E16F97535C4 Q26823281-5D49C2A9-48E0-4EA7-8A1A-F073EBEA279B Q26825208-F65BB15E-E4A7-406F-A3B4-045706B94C69 Q26852762-EB4B5B20-26DD-4285-BD20-9089B9F4DAE4 Q27000194-EE31F427-843B-4BE7-A494-9B741F056589 Q27011330-9A5F3130-E28C-44B1-970A-CEB582E75947 Q28079861-2EEE443E-4AF4-4174-BCCA-8FC3EBD74403 Q28084366-234A5FD6-EAE3-4B83-B5DE-D29DA45B09CC Q28749508-C5ABD88C-D6C1-4C95-B5CC-B51948D27584 Q30482901-B51ECA2C-774D-4C1D-8D4F-160FB860660E Q30983921-56076F0A-9A3C-4302-AF10-A2D050E69213 Q31108592-299EFB3C-408B-454B-B32D-60DDF9966B8F Q33242978-C63B5545-F336-4724-970A-F250FA484BCB Q33376348-C1068D6A-7191-4D87-8608-928AB42C8713 Q33412367-ED0CDEA5-27D6-4ABA-8BB8-6BFE5B31F0BA Q33521351-1424E667-D151-4DF9-88E6-BF26917C0E5C Q33530170-DA90D034-B625-45A1-B794-8229FB45574E Q33566872-FB3CA5DE-785C-4405-8F85-08511CCFABC9 Q33604754-9FBAAC16-13D8-4FAE-BEE9-34F6D167E037 Q33688908-3A11C05C-D7D5-4892-BAC3-1DBE579E188B Q33761278-03C1C6B6-B027-449A-9309-3D6568610614 Q33806121-E15A72FE-951E-4E79-BC13-2F840DDEB629 Q33860323-638B04CE-2586-436C-A8D6-3F4E1FC4390E Q33891730-5D80D8C0-910E-49BD-B1E1-CA288A194646 Q33891755-2D8DBC09-B68E-4F81-8765-D6D00F7D6BA8 Q33985467-DBB11DEB-6DA4-484A-AF36-39382884A29E Q33996931-9DEE7DBD-FAB4-48EA-82EF-285CFFA46B24 Q34011801-8FE3AE0A-09B9-4A6E-A169-C017811BD947 Q34048053-F2A2C862-FAB0-4016-A8BD-44D77BB52406 Q34487603-E3959A05-9B5A-4764-82BA-3BACFE812311 Q34497217-F08C17CB-0401-4E1A-B510-A699619E96F5 Q34610933-6C9B08DB-1B6B-424C-8F0F-BD62D2D27F49 Q34635688-4B93208A-ACFA-42FA-B07E-7A1C98ED5A4C

P2860

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.

http://www.wikidata.org/entity/Q33968031

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Everolimus for the prevention ...... cardiac-transplant recipients.

@ast

Everolimus for the prevention ...... cardiac-transplant recipients.

@en

type

label

Everolimus for the prevention ...... cardiac-transplant recipients.

@ast

Everolimus for the prevention ...... cardiac-transplant recipients.

@en

prefLabel

Everolimus for the prevention ...... cardiac-transplant recipients.

@ast

Everolimus for the prevention ...... cardiac-transplant recipients.

@en

P1433

Q33968031-3992042D-125E-4646-B48A-9AE7DBAB20B4

P1476

Q33968031-832B6C04-CD45-486D-B8E2-CBF4EFB1AE7B

P2093

Q33968031-1F72B8C2-FECE-4F66-B6C6-3F13296D8B6E

Q33968031-3A72C489-9D96-4322-8001-8FF63E1198E0

Q33968031-3BA07EFD-C38F-48DD-BF3F-6D5005D6985F

Q33968031-47E6793E-4EBA-4B9A-8E95-E6E32B2CF2B2

Q33968031-55EB25E8-AF5D-4AC1-BA15-08377F405675

Q33968031-5C382EF2-5E1A-4629-B276-FF47F91BBB04

Q33968031-7BC6D065-CAB6-4B63-AC86-6792EE633ED6

Q33968031-7C501976-9F93-4D8A-A071-B33E228C6079

Q33968031-BFA76229-17BA-4A62-96D1-0252B0C8A8BD

Q33968031-C17A33E1-B307-4DED-BC0E-CC9CEC2D2515

P304

Q33968031-B1C5A27C-9B49-47E9-BB64-CBDD99F5F53F

P31

Q33968031-72F883D2-36B8-4AF8-A9B1-24767FE59B51

P356

Q33968031-7088DC94-A1F9-4610-AC87-F924C1FDEA92

P407

Q33968031-73092FD9-D714-46AD-A8F9-D4B9F4C4DC98

P433

Q33968031-AE11F6A8-17F9-4373-9628-D8D9D04D522A

P478

Q33968031-2DAC877E-3A53-4456-B41B-0CF41404AA00

P50

Q33968031-2D8C87F0-97F3-4B98-96AE-6C7AF122826D

P577

Q33968031-68AD49F4-4F90-486F-AEB6-984B87DFC0AB

P5875

Q33968031-EB1E5CD5-2994-419A-9309-D5CE140248F8

P698

Q33968031-EF91725F-2DED-4A56-91A9-CB739D0F6C50

P356

P1433

The New England Journal of Medicine

P1476

Everolimus for the prevention ...... cardiac-transplant recipients.

@en

P2093

Donna Mancini

http://www.w3.org/2001/XMLSchema#string

E Murat Tuzcu

http://www.w3.org/2001/XMLSchema#string

Hannah A Valantine-von Kaeppler

http://www.w3.org/2001/XMLSchema#string

Howard J Eisen

http://www.w3.org/2001/XMLSchema#string

Joan M Lind

http://www.w3.org/2001/XMLSchema#string

Jon Kobashigawa

http://www.w3.org/2001/XMLSchema#string

Kamal H Abeywickrama

http://www.w3.org/2001/XMLSchema#string

Keld Sørensen

http://www.w3.org/2001/XMLSchema#string

Manfred Hummel

http://www.w3.org/2001/XMLSchema#string

Peter Bernhardt

http://www.w3.org/2001/XMLSchema#string

P304

847-858

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA022171

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

349

http://www.w3.org/2001/XMLSchema#string

P50

Randall C Starling

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10591786

http://www.w3.org/2001/XMLSchema#string

P698

12944570

http://www.w3.org/2001/XMLSchema#string